CollPlant Biotechnologies (CLGN) Receivables (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Receivables came in at $1000.0 in Q4 2025, down 100.0% YoY from $150.0 million in Q4 2024, and down 100.0% on a QoQ basis from $150.0 million in Q4 2024.
CollPlant Biotechnologies (CLGN) Receivables (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Receivables data on file, last reported at $1000.0 in Q4 2025.
- Quarterly Receivables fell 100.0% year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1000.0 (down 100.0% YoY) and the FY2025 annual result came in at $1000.0, down 100.0% from the prior year.
- Receivables slipped to $1000.0 in Q4 2025, from $150.0 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $270.0 billion in Q4 2021 to a low of -$463000.0 in Q2 2021.
- A 5-year average of $18.0 billion and a median of $4.0 million in 2023 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 31358763.53% in 2021, down 191.19% in 2021.
- Tracing CLGN's Receivables over 5 years: stood at $270.0 billion in 2021, then sank by 100.0% to $8.9 million in 2022, then tumbled by 54.4% to $4.0 million in 2023, then soared by 3603.7% to $150.0 million in 2024, then slumped by 100.0% to $1000.0 in 2025.
- The last three Receivables figures came in at $1000.0 (Q4 2025), $150.0 million (Q4 2024), and $5.0 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 150.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 90.00 Mn |
| Sep 30, 2023 | 4.05 Mn |
| Jun 30, 2023 | 10.16 Mn |
| Mar 31, 2023 | 458,000.00 |
| Dec 31, 2022 | 8.88 Mn |
| Sep 30, 2022 | -56,000.00 |
| Jun 30, 2022 | -161,000.00 |
| Dec 31, 2021 | 270.00 Bn |
| Sep 30, 2021 | -369,000.00 |
| Jun 30, 2021 | -463,000.00 |
| Mar 31, 2021 | 173.97 Mn |
| Dec 31, 2020 | 861,000.00 |
| Sep 30, 2020 | 611,000.00 |
| Jun 30, 2020 | -159,000.00 |
| Mar 31, 2020 | 455,000.00 |
| Dec 31, 2019 | 79.04 Mn |